Eric Venker
CIK 1801917 · President & Immunovant CEO · last filed 2026-05-22
Eric Venker is a President & Immunovant CEO who has filed 83 SEC Form 4 insider transactions across 3 companies since 2022. The most recent filing, for ROIV, was dated May 22, 2026. Across all open-market trades the lifetime net is −$180.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $56.9M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$56.92M
3
83
-$180.01M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ROIV | President & Immunovant CEO | 1,613,063 | $30.04 | $48.46M | -$156.30M | 48 | 2026-05-22 |
| IMVT | Chief Executive Officer | 251,813 | $33.62 | $8.47M | -$342.9K | 3 | 2026-04-09 |
| Roivant Sciences Ltd. (ROIVW) Delisted | President & COO | 611,813 | $2.75 | $1.68M | -$23.37M | 32 | 2023-08-24 |
Recent Filings
83 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-22 | ROIV | Mixed | −34,483 | -$6.40M | EDGAR |
| 2026-04-22 | ROIV | Mixed | — | -$5.15M | EDGAR |
| 2026-04-09 | IMVT | Grant (A) | +232,252 | $0 | EDGAR |
| 2026-04-03 | IMVT | Mixed | +19,561 | -$3.42M | EDGAR |
| 2026-03-19 | ROIV | Mixed | — | -$4.88M | EDGAR |
| 2026-02-24 | ROIV | Tax (F) | −7,051 | -$191.4K | EDGAR |
| 2026-02-18 | ROIV | Mixed | — | -$4.53M | EDGAR |
| 2026-01-14 | ROIV | Mixed | — | -$3.61M | EDGAR |
| 2025-12-29 | ROIV | Mixed | +156,689 | -$4.52M | EDGAR |
| 2025-12-11 | ROIV | Mixed | — | -$3.40M | EDGAR |